eversyn & Max Planck Institute DCTS


eversyn is a spin-off of the Max Planck Institute Magdeburg – run and founded by Max Planck Society scientists and business professionals. With our scalable glycoengineering platform, we provide full control over protein glycosylation - independent of upstream processing. We aim to tailor any glycoform to our customer needs. Our vision is to improve the efficacy and safety of next-generation biopharmaceuticals and help to develop biosimiliars & biobetters. Visit our website to learn: www.eversyn.de